{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/seborrhoeic-dermatitis/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"f384b060-7f9e-593e-8a77-6bbf957fd0c4","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field b2f590d5-3280-474d-b47c-602a722ac961 --><h2>How should I assess a person with suspected seborrhoeic dermatitis?</h2><!-- end field b2f590d5-3280-474d-b47c-602a722ac961 -->","summary":"","htmlStringContent":"<!-- begin item f9e830f7-9d15-4568-adc9-faa8da419c34 --><!-- begin field 532c6468-03ca-47a8-8469-d2fc94c7c87d --><p><strong>Take a history asking about:</strong></p><ul><li>Onset, evolution and distribution of <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/diagnosis/clinical-features/\">clinical features</a> such as erythema, scaling and pruritus.</li><li>Associated features such as failure to thrive in an infant and impaired immunity which are suggestive of an <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/background-information/causes/\">underlying condition</a> especially in those presenting with sudden onset of severe or extensive seborrhoeic dermatitis.</li><li>Past medical history including <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/background-information/causes/\">conditions which may predispose</a> to seborrhoeic dermatitis such as HIV and Parkinson’s disease.</li><li>Drugs – some drugs are associated with seborrhoeic dermatitis including chlorpromazine, cimetidine, gold, haloperidol, interferon‐alpha, lithium, and methyldopa.</li></ul><p><strong>Examine the person looking for:</strong></p><ul><li><a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/diagnosis/clinical-features/\">Typical features</a> of seborrhoeic dermatitis such as erythematous scaly patches in areas rich in sebaceous glands — severity can vary from mild flaking to widespread, oily, dense scaling or crusting.</li></ul><p><strong>Consider the need for further investigations:</strong></p><ul><li>Diagnosis is usually clinical — investigations (such as blood tests, skin scrapings, or skin biopsy) may be appropriate if an underlying cause (such as HIV) or <a class=\"topic-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/diagnosis/differential-diagnosis/\">alternative diagnosis</a> (such as tinea or lupus) are suspected.</li></ul><!-- end field 532c6468-03ca-47a8-8469-d2fc94c7c87d --><!-- end item f9e830f7-9d15-4568-adc9-faa8da419c34 -->","topic":{"id":"b328d01a-a44a-57e1-8920-22321b4c6c8b","topicId":"67c69cb5-e030-443e-802f-758ce0fe90f8","topicName":"Seborrhoeic dermatitis","slug":"seborrhoeic-dermatitis","lastRevised":"Last revised in February 2019","chapters":[{"id":"2c32aabf-f751-57c2-9fb1-bfd7e4c7e58d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"96bfb0b4-09f0-5525-aaf3-ca2354a87cb4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9bf8c16e-f128-5c6a-b6e8-d4223dcf2346","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"debcdac6-7ef3-5820-90b8-353614354fc7","slug":"changes","fullItemName":"Changes"},{"id":"32308918-ad23-5b7d-a1c5-7c7a4edf3e35","slug":"update","fullItemName":"Update"}]},{"id":"efc69a37-1a91-539d-b4ce-b1cfc1d48baf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"09ce3910-2aa3-537d-97db-f473bf3f3c99","slug":"goals","fullItemName":"Goals"},{"id":"37776aed-67d4-5001-8e82-0fec56ecaa71","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2638b372-65f4-549c-9c2d-fff4cf1c933d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"df03f868-28e0-52a9-9f30-aecfccaa745c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bf290438-2d1b-5233-a43a-e3fe0cbccaab","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d66aeca6-f9ff-5104-94d3-d115d20ad7d1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5f9559ed-2d1c-52f3-ae50-cb983d1b7c7c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025302eb-268d-585c-b9a4-d83b4dbb0e5b","slug":"definition","fullItemName":"Definition"},{"id":"43d0a434-92b2-5c53-b4bd-f8ab32a8c0a3","slug":"causes","fullItemName":"Causes"},{"id":"0f04315e-ba03-5be7-a5dc-c724c1e3fe90","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad49e37a-e725-5ad1-9e7b-f84a79627169","slug":"complications","fullItemName":"Complications"},{"id":"50cfb7dd-1ad7-5d22-9c7e-8472fb0af48c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26dec6e1-8806-50b7-869d-1e010fa15e89","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f674962-dade-5ce5-9b92-60820da005f7","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"f384b060-7f9e-593e-8a77-6bbf957fd0c4","slug":"assessment","fullItemName":"Assessment"},{"id":"2b98bc5c-ae88-522e-89c4-79e05d301c3f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"521d1a4a-9184-5872-ab66-2a3fed074cc8","fullItemName":"Management","slug":"management","subChapters":[{"id":"ca5edad5-d74c-565f-b254-2c59bed62420","slug":"seborrhoeic-dermatitis-infants","fullItemName":"Scenario: Seborrhoeic dermatitis - infants"},{"id":"4172af9c-8f8b-5bcc-a160-ca83f520099c","slug":"seborrhoeic-dermatitis-scalp-beard","fullItemName":"Scenario: Seborrhoeic dermatitis - scalp and beard"},{"id":"ad81b0ed-2e0c-5a1d-a7a0-e823d40d7ca4","slug":"seborrhoeic-dermatitis-face-body","fullItemName":"Scenario: Seborrhoeic dermatitis - face and body"},{"id":"715da1f8-f458-5eec-96e8-85e22060d505","slug":"seborrhoeic-dermatitis-severe-or-widespread","fullItemName":"Scenario: Seborrhoeic dermatitis - severe or widespread"}]},{"id":"bac53cb4-0b97-5d4b-8ce4-07a9584a5e4f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"970b1e50-a3fc-503d-bbe8-29ecfa575d20","slug":"products-available-otc","fullItemName":"Products available OTC"},{"id":"9b1c8434-e7ce-5cd0-8c49-9e1076fbcecb","slug":"topical-imidazoles","fullItemName":"Topical imidazoles"},{"id":"d35c5c70-d96b-5a9a-a708-2e051cf3cece","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"}]},{"id":"b5cb8438-116a-5790-9b0f-2a480c577056","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"03823e51-3fec-53db-8dde-3fbe6e94526c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"364fda13-808d-599d-84cd-2b31ed7d0d94","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fd9a5e23-6ee9-503f-bbc4-7239d8555e0e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1120e62a-fd06-536e-8caf-945332e36549","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"214850c4-e7af-5924-9a63-09325facd062","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bfa9b404-d181-55eb-a3b2-8da0ee4edb43","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"5171db55-6873-590e-b670-2d66a4b1b1eb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"26dec6e1-8806-50b7-869d-1e010fa15e89","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"e830fbe8-3c37-5596-9f82-53cf033433fa","slug":"basis-for-recommendation-348","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 2c54c40c-835d-4b73-9547-9ddebf9efc1c --><h3>Basis for recommendation</h3><!-- end field 2c54c40c-835d-4b73-9547-9ddebf9efc1c -->","summary":null,"htmlStringContent":"<!-- begin item 348945ed-1164-4ffc-97ab-8181fa26235a --><!-- begin field 2df52286-bf1b-41eb-b73f-9902b84ecc74 --><p>The recommendations on how to assess a person with suspected seborrhoeic dermatitis are based on clinical guidance from the World Health Organisation <em>Evidence and recommendations on seborrhoeic dermatitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>], <em>Evidence-based Danish guidelines for the treatment of Malassezia-related skin diseases</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>] and the Primary Care Dermatological Society <em>Seborrhoeic eczema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">PCDS, 2016</a>], and expert opinion from the British Association of Dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>], Rook’s textbook of dermatology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>] and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Gary, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Kastarinen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Borda, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Okokon, 2015</a>].</p><h4>Assessment</h4><ul><li>Consensus opinion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Dessinioti, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Kastarinen, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Ooi, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Clark, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Hald, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Okokon, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">Wakelin, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">BAD, 2018</a>] is that diagnosis of seborrhoeic dermatitis can be made clinically based on a thorough history and examination — investigations such as skin biopsy and blood tests are not usually necessary unless an alternative diagnosis (such as tinea) or underlying cause (such as HIV) or is suspected.</li><li>Extensive severe seborrhoeic dermatitis is considered to be a marker of immunodeficiency in both children and adults — consider the need for further testing (for example to exclude HIV) or referral [<a class=\"bibliography-reference internal-reference\" href=\"/topics/seborrhoeic-dermatitis/references/\">WHO, 2014</a>].</li></ul><!-- end field 2df52286-bf1b-41eb-b73f-9902b84ecc74 --><!-- end item 348945ed-1164-4ffc-97ab-8181fa26235a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}